SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Angiology
This Article
Right arrow Full Text (OnlineFirst PDF)
Right arrow All Versions of this Article:
0003319707312518v1
59/3/323    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Kallistratos, M. S.
Right arrow Articles by Cokkinos, D. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kallistratos, M. S.
Right arrow Articles by Cokkinos, D. V.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Article

N-terminal Prohormone Brain Natriuretic Peptide Plasma Levels in Heart Failure Are Affected Both Directly and Indirectly by Carvedilol

Manolis S. Kallistratos*, Athanasios Dritsas, MD, Ioannis D. Laoutaris, PhD, and Dennis V. Cokkinos, DV, MD

* To whom correspondence should be addressed. E-mail: mankal1{at}otenet.gr.


  Abstract
N-terminal prohormone brain natriuretic peptide (NT Pro BNP) is a sensitive marker of left ventricular function in patients with heart failure. The influence of carvedilol on NT Pro BNP plasma levels was analyzed in 21 heart failure patients. Blood samples were taken before administration and after 12 months of treatment with low-dose carvedilol. Peak oxygen consumption did not change after carvedilol treatment, left ventricular ejection fraction improved (P < .005) in 11 patients (52%), did not change in 9 (43%), and decreased in 1 (5%). In patients where left ventricular ejection fraction improved, NT Pro BNP tended to decrease; however, in patients without improvement, NT Pro BNP increased at follow-up. A correlation exists between magnitude of change in BNP and magnitude of improvement in ventricular function during carvedilol therapy. Patients without noticeable changes in left ventricular ejection fraction with a low to moderate carvedilol dosage show an increase in NT Pro BNP plasma levels.

First published on April 2, 2008, doi:10.1177/0003319707312518

Angiology 2008;59:323.

A more recent version of this article appeared on July 1, 2008

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement